SQZ Biotechnologies Co Ordinary Shares SQZB
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.02–0.02
- 52-Week Range
- $0.02–0.05
- Bid/Ask
- $0.04 / $0.05
- Shares Outstanding
- 29.49M
- Market Cap
- $707,787.00
- Volume/Avg
- 20,638 / 2,391
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 53
- Website
- https://www.sqzbiotech.com
Valuation
|
Metric
|
SQZB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SQZB
|
|---|---|
Quick Ratio | 1.15 |
Current Ratio | 1.37 |
Interest Coverage | — |
Quick Ratio
SQZB
Profitability
|
Metric
|
SQZB
|
|---|---|
Return on Assets (Normalized) | −66.45% |
Return on Equity (Normalized) | −142.33% |
Return on Invested Capital (Normalized) | −80.39% |
Return on Assets
SQZB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@rL!Z> | LOCK|t&SV | $128B | |||
| Moderna Inc
MRNA
| LOCK|&h>R!&? | LOCK|QP | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!Gf>Qy | LOCK|&Cb&^ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|H#&$XX | LOCK|Z@ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vt>JT@ | LOCK|T% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?FR<mY | LOCK|Kv#?# | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|crznJ^<m | LOCK|^vRq | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^yz@Zc | LOCK|l^R | $24B | |||
| Incyte Corp
INCY
| LOCK|<z&#N# | LOCK|p$l | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|FKg@qC | LOCK|SZ | $15B |
United States